GNH USA

Europe — EMA

Octreoscan (Indium In-111 Pentetreotide)

GNH USA supplies Octreoscan (Indium In-111 Pentetreotide), a radiopharmaceutical for imaging neuroendocrine tumors. Request a quote for global supply.

Indium In-111 Pentetreotide

Request sourcing

1
Pack/s

What is Indium In-111 Pentetreotide?

Indium In-111 Pentetreotide, the active ingredient in Octreoscan, is a radiopharmaceutical presented as a sterile solution for intravenous use. It binds to somatostatin receptors and is employed for diagnostic imaging of somatostatin‑receptor positive neuroendocrine tumors in adult patients.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

What is Indium In-111 Pentetreotide used for?

Octreoscan is used in diagnostic imaging of somatostatin receptor‑positive neuroendocrine tumors.

- Neuroendocrine tumors (NETs): enables whole‑body scintigraphy to locate primary and metastatic lesions. - Carcinoid tumors: assists in staging and treatment planning by visualising receptor‑expressing disease. - Medullary thyroid carcinoma: detects somatostatin receptor expression for disease assessment. - Pheochromocytoma and paraganglioma: images receptor‑positive lesions to guide management.

What are the side effects of Indium In-111 Pentetreotide?

Common Side Effects: - Nausea: mild, transient after injection. - Flushing: brief sensation of warmth or redness. - Injection site pain: mild discomfort at the venipuncture site. - Headache: occasional, self‑limiting. - Transient hypotension: short‑lasting drop in blood pressure. - Mild abdominal discomfort: brief and usually resolves.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis: requires immediate medical attention. - Significant hypotension: may need supportive measures. - Radiation‑induced marrow suppression: rare, monitor blood counts. - Renal toxicity: possible in patients with pre‑existing kidney impairment. - Severe bronchospasm: especially in patients with reactive airway disease. - Acute radiation syndrome: extremely rare, associated with dosing errors.

What precautions apply to Indium In-111 Pentetreotide?

Octreoscan should be used with careful consideration of patient‑specific factors and handling requirements. - Pregnancy: avoid unless essential; radiation may harm the fetus. - Breastfeeding: discontinue breastfeeding for the period recommended by the prescribing physician. - Renal function: assess before administration as the agent is cleared renally. - Known hypersensitivity: screen for allergy to pentetreotide or indium compounds. - Concurrent radiopharmaceuticals: avoid administration of other diagnostic radionuclides within 24 hours. - Store at ambient temperature: keep in original shielding container, protect from light and moisture.

What does Indium In-111 Pentetreotide interact with?

Octreoscan may interact with other agents that affect receptor binding or radiation exposure.

Major Interactions (Avoid): - Other radiopharmaceuticals (e.g., I‑131) within 24 h: may cause imaging interference. - High‑dose somatostatin analog therapy (e.g., octreotide): competes for receptor sites and reduces uptake. - Cytotoxic chemotherapy causing severe marrow suppression: may increase radiation toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of the agent. - ACE inhibitors: can potentiate hypotensive effects. - Contrast agents used in CT: may affect interpretation of scintigraphic images. - Antihistamines: may mask mild allergic reactions. - Beta‑blockers: could influence cardiovascular response to the injection.

Frequently asked questions

What is Octreoscan used for?+
Octreoscan is a radiopharmaceutical used for diagnostic imaging of somatostatin‑receptor positive neuroendocrine tumors, including carcinoid tumors, medullary thyroid carcinoma, and pheochromocytoma. It helps clinicians locate primary and metastatic disease sites by visualising receptor expression with gamma‑camera imaging.
How does Indium In-111 Pentetreotide work?+
Indium In-111 Pentetreotide is a somatostatin analog labeled with the gamma‑emitting radionuclide indium‑111. After intravenous injection it binds with high affinity to somatostatin receptors (especially subtype sst2) on tumor cells. The bound radionuclide emits photons that are detected by a gamma camera, producing detailed images of receptor‑expressing tissues.
What is the usual dose of Octreoscan?+
The dose of Octreoscan is determined by the prescribing physician based on the patient’s weight, clinical indication, and imaging protocol. The healthcare professional calculates the appropriate activity (megabecquerels) and administers the product intravenously under controlled conditions.
Is Octreoscan safe during pregnancy or breastfeeding?+
Octreoscan is generally contraindicated in pregnancy because the radiation could affect the developing fetus. It is also not recommended during breastfeeding; mothers should discontinue nursing for the period advised by the treating physician to avoid radiation exposure to the infant.
How do I order Octreoscan from GNH USA?+
To order Octreoscan, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.
How does Octreoscan compare with other imaging agents for neuroendocrine tumors?+
Octreoscan offers high specificity for somatostatin receptor‑positive lesions, providing whole‑body scintigraphy. Compared with newer PET agents such as 68Ga‑DOTATATE, Octreoscan has lower spatial resolution but remains useful where PET facilities are unavailable. Choice of agent depends on local imaging capabilities, regulatory approval, and clinical context.
What are the storage and handling requirements for Octreoscan?+
Octreoscan should be stored at ambient temperature, preferably below 25 °C, in its original shielding container. Protect the vial from light, moisture, and physical damage. Do not freeze. Use aseptic technique when withdrawing the solution for intravenous administration.
How is Octreoscan administered?+
Octreoscan is administered as a single intravenous injection under sterile conditions. The prescribed activity is drawn into a syringe and injected slowly, typically followed by a waiting period (usually 24 hours) before imaging to allow optimal tumor uptake and background clearance.
What are the most serious risks associated with Octreoscan?+
The most serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced marrow suppression, and renal toxicity in patients with impaired kidney function. Patients should be monitored during and after injection for any signs of these adverse events.
Who should not use Octreoscan?+
Octreoscan should not be used in patients with known hypersensitivity to pentetreotide or indium‑111, in pregnant women unless absolutely necessary, in breastfeeding mothers without appropriate interruption, and in individuals with severe renal impairment without dose adjustment or specialist supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Indium In-111 Pentetreotide
Route
Intravenous Use
Manufacturer
Curium Netherlands B.V.
Origin
EU

Related products

Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Belgium Bv
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU